Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q7RTS3
UPID:
PTF1A_HUMAN
Alternative names:
Class A basic helix-loop-helix protein 29; Pancreas-specific transcription factor 1a; bHLH transcription factor p48; p48 DNA-binding subunit of transcription factor PTF1
Alternative UPACC:
Q7RTS3; Q9HC25
Background:
Pancreas transcription factor 1 subunit alpha, also known as PTF1A, plays a pivotal role in pancreas development and differentiation. It binds to E-box consensus sequences, influencing cell fate in various organs. PTF1A is crucial for the formation of pancreatic acinar and ductal cells and has a significant role in cerebellar development.
Therapeutic significance:
PTF1A is linked to Pancreatic and cerebellar agenesis and Pancreatic agenesis 2, diseases characterized by diabetes mellitus and pancreatic insufficiency. Understanding PTF1A's role could unveil new therapeutic strategies for these conditions.